

# A One-Year Assessment of Quality Indicators within an Apheresis-Only Center Operated by a Large Dialysis Provider

Vicki Chapman, RN, HP (ASCP)

Joanne Brady, RN, MBA

Elon Levine

Robert Provenzano, MD

*DaVita Inc., Denver, CO*



# Introduction

- Limited published apheresis patient information on
  - Safety procedures
  - Quality indicators in the provision of apheresis treatments.



# Acute Clinical Outcome Indicators (ACOI) Form

- Goal Collect patient data per apheresis treatment in an effort to:
  - improve patient safety,
  - enhance communication among patient care teams,
  - understand the nursing care given,
  - optimize clinical outcomes for patients, and
  - partner with hospitals for optimal Joint Commission\* survey results.

\*Questions based on 2010 TJC Standards



# Objective

- To collect and present key indicators of clinical outcomes and process of care measures using the ACOI form data from each treatment.



# Methodology

- ACOI form data:
  - Jan 2010 – Dec 2010
  - Collected by 6 apheresis RNs in 12 contracted hospitals
  - Reported and assessed monthly
- Random chart audits ensured consistency between the ACOI form and treatment flowsheet.



# Treatment Characteristics

	Number	Percent
<i>Total Treatments</i>	<i>1206</i>	
Therapeutic Plasma Exchanges	1157	96%
Red Cell Exchanges	19	1.6%
White Cell Depletions	27	2.2%
Platelet Depletions	3	0.2%

- The majority of treatments were out-patient (57.2%)

# Results

Question		2010 Goal	2010 Actual
Signs and/or symptoms of infection present	% of Yes	≤15%	3.0%
Post apheresis vascular access site bleeding ≥20 minutes	% of Yes	≤5%	2.2%
System clotted during treatment	% of Yes	≤20%	0.7%
Assessed pain prior to treatment initiation	% of Yes	≥90%	98.9%
Maintenance anticoagulant delivered per pump	% of No	0%	0.1%
Procedure education provided to patient and/or family	% of Yes	≥75%	98.9%

# Limitations of the Study

- As the majority of treatments were performed in the outpatient setting, responses related to hospital communication were not reported in this abstract.



# Conclusions

- Our 2010 ACOI goals were met.
- The ACOI form:
  - allowed tracking of pertinent clinical outcomes during apheresis treatments.
  - can be used to assure patients, payers and healthcare providers of the value of the prescribed therapy.



# Next Steps

- This 12-month data set will be used to establish a benchmark to allow assessment of future quality initiatives.
- Development of Continuous Quality Improvement (CQI) projects to improve patient safety and enhance clinical outcomes.



# Acknowledgement

- We thank the acute nurses who work every day not only to take care of patients but also to ensure the extensive data collection on which our work is based.
- We thank DaVita Clinical Research<sup>®</sup> (DCR<sup>®</sup>) for preparation of this presentation. DCR is committed to advancing the knowledge and practice of kidney care.

